Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT06509009 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma by AJCC V8 Stage

Interventions

DRUG: Nimotuzumab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences